Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8278531 | 1.00 | NOTUM (0.48) | NOTUMTDP1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL3154327 | 0.86 | ACE (0.54) | NOTUMTDP1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL13971489 | 0.86 | ACE (0.54) | NOTUMTDP1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL2092090 | 0.86 | ACE (0.54) | NOTUMTDP1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL32676972 | 0.86 | ACE (0.54) | NOTUMTDP1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL32676817 | 0.84 | HTR1A (0.43) | NOTUMTDP1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL32676643 | 0.84 | HTR1A (0.43) | NOTUMTDP1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL13619651 | 0.84 | HTR1A (0.43) | NOTUMTDP1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL32676967 | 0.84 | HTR1A (0.43) | NOTUMTDP1POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL21515929 | 0.83 | NOTUM (0.47) | NOTUMPOLBHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-8653054-B2 | 2-(N-substituted piperazinyl) steroid derivatives | UNIVERSITE LAVAL (CA) | 2014-02-18 | — | — | US | disclosed |
| US-8653054-B2 | 2-(N-substituted piperazinyl) steroid derivatives | UNIVERSITE LAVAL (CA) | 2014-02-18 | — | — | US | disclosed |
| US-20120252734-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | OLSON GARY LEE (US) | 2012-10-04 | — | — | US | disclosed |
| US-8222215-B2 | Methods for the use of inhibitors of antigen presentation by MHC class II molecules | PROVID PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | UNIVERSITE LAVAL (CA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | UNIVERSITE LAVAL (CA) | 2011-12-22 | — | — | US | disclosed |
| US-7759459-B2 | Fluorescent assays for protein kinases | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759459-B2 | Fluorescent assays for protein kinases | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | PROVID PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| EP-1006122-B1 | PHENETHYLAMINE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-7439231-B2 | Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof | PROVID PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | TFPI, F11, F13B | NOTUM 704/4885TDP1 2533/4885POLB 2381/4885 |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ACIN1, CYCS, CASP7 | NOTUM 2060/4885TDP1 2730/4885POLB 2207/4885 |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | HLA-DRB1, CD74, MICA | NOTUM 1341/4885TDP1 3779/4885POLB 1457/4885 |
| US-20120252734-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | HLA-DRB1, CD74, MICA | NOTUM 1498/4885TDP1 3972/4885POLB 2384/4885 |
| US-20110312926-A1 | 2-(N-Substituted Piperazinyl) Steroid Derivatives | NR5A1, HSD17B11, CYP17A1 | NOTUM 1771/4885TDP1 4344/4885POLB 1888/4885 |
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | OXTR, AVPR2, AVPR1B | NOTUM 2621/4885TDP1 2427/4885POLB 4688/4885 |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | NOTUM 321/4885TDP1 736/4885POLB 2502/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | NOTUM 321/4885TDP1 736/4885POLB 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.